Research
Hypoxia signalling is crucial in normal physiological function as it orchestrates adaptive responses to low oxygen levels, promoting the activation of key pathways that regulate cellular metabolism and ensure tissue survival. Conversely, its dysregulation of is implicated in various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, highlighting its potential as a therapeutic target for mitigating pathological processes. Our work is aimed at defining hypoxia-dependent signalling pathways to uncover new biomarkers and drug targets for human disease.
Research grants
Deubiquitinase Inhibitors as Novel Therapeutics for the Treatment of Hypoxic Lung Tumours and Mesothelioma
WORLDWIDE CANCER RESEARCH (UK)
March 2024 - February 2027
Deubiquitinase Inhibitors as Novel Therapeutics for the Treatment of Hypoxic Malignant Pleural Mesothelioma.
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
February 2024 - January 2025